Medicare Coverage Restrictions For Expensive Drugs: Did Aduhelm Let The Genie Out Of The Bottle?
Payer discomfort with accelerated approvals exploded into the public arena with the Medicare national coverage determination on Aduhelm and similar drugs, and developers worry that the fallout will be far reaching.
You may also be interested in...
CMS chief medical officer Lee Fleisher addresses concerns that the Medicare national coverage determination for Alzheimer’s drugs sets a precedent for accelerated approvals. He and the FDA's Janet Woodcock also discuss prospects for closer collaboration on evidence needs pre-approval.
Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.
Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure responds to US Congressional concerns about the proposed Medicare coverage policy for Alzheimer’s drugs.